University of Texas Medical Branch

GeoVax to Participate in Upcoming November Investor and Industry Events

Retrieved on: 
Wednesday, October 25, 2023

ATLANTA, GA, Oct. 25, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that members of its senior management team and other scientific representatives will participate in four upcoming investor and industry events during November.

Key Points: 
  • ATLANTA, GA, Oct. 25, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that members of its senior management team and other scientific representatives will participate in four upcoming investor and industry events during November.
  • Event details are as follows:
    For more information and to register to attend the GeoVax Presentation, please visit Emerging Growth Conference .
  • Senior GeoVax management will host one-on-one meetings with registered attendees.
  • If interested in meeting with management at this event, please contact the company through the conference portal, or directly at [email protected].

PayZen Launches Innovative Financial Solution for Affordable Care with The Care Card & Partners with Geisinger & UTMB

Retrieved on: 
Tuesday, October 3, 2023

SAN FRANCISCO, Oct. 3, 2023 /PRNewswire/ -- PayZen, a healthcare focused fintech company tackling healthcare affordability with AI-powered patient affordability solutions, today announced the release of its newest product, the PayZen Care Card, with its major launch partners Geisinger and University of Texas Medical Branch (UTMB).

Key Points: 
  • The Care Card is PayZen's second product and expands on the highly successful post care payment plan solution.
  • PayZen uses advanced technology to solve healthcare affordability end-to-end, leading to happier, healthier patients, and improved financial outcomes for providers.
  • The Care Card addresses the growing problem of patients putting off care due to cost, improving healthcare access and providing financial peace of mind for consumers.
  • Once patients understand their out-of-pocket costs, the Care Card ensures that they will have a way to pay for their care.

Aidoc's AI Solution for Pulmonary Embolism Clinically Proven to Reduce Hospital Stay Duration and Improves Patient Access to Treatment

Retrieved on: 
Friday, September 22, 2023

AUSTIN, Texas, Sept. 22, 2023 /PRNewswire/ -- Groundbreaking research in the advancement of AI-driven pulmonary embolism (PE) care was unveiled yesterday evening during the 9th Annual Pulmonary Embolism Symposium. Research from three leading institutions utilizing Aidoc's PE AI solution demonstrated immense clinical value in reducing mean hospital length of stay, improving patient access, and correctly alerting care teams of suspected PEs with potential for advanced interventions.

Key Points: 
  • Research from three leading institutions utilizing Aidoc's PE AI solution demonstrated immense clinical value in reducing mean hospital length of stay, improving patient access, and correctly alerting care teams of suspected PEs with potential for advanced interventions.
  • The three studies highlighted the care advantages of utilizing Aidoc in the management of acute pulmonary embolisms, including numerous patient outcome benefits.
  • Key findings from the studies presented include:
    "Proving the robustness of any AI solution hinges on the application of scientific rigor and the scrutiny of peer review.
  • These studies illustrate the ongoing evolution of Aidoc's AI-powered PE solution from an algorithm to enterprise-wide platform used by Pulmonary Embolism Response Teams (PERTs) across entire health systems.

GeoVax Announces Issuance of Ebola Vaccine Patent

Retrieved on: 
Monday, July 24, 2023

ATLANTA, GA, July 24, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that the U.S. Patent and Trademark Office has issued Patent No. 11,701,418 B2 to GeoVax, pursuant to the Company’s patent application No. 15/543,139 titled “Replication-Deficient Modified Vaccinia Ankara (MVA) and Matrix Protein (VP40).”

Key Points: 
  • 11,701,418 B2 to GeoVax, pursuant to the Company’s patent application No.
  • GeoVax previously demonstrated that a single intramuscular (IM) dose of its vaccine candidate, GEO-EM01, provided 100% protection in rhesus macaques challenged with a lethal dose of Zaire ebolavirus (EBOV).
  • Dr. Jason Comer of Sealy Institute for Vaccine Sciences, University of Texas Medical Branch (UTMB), recently discussed GeoVax’s Sudan virus vaccine efficacy.
  • This patent allowance adds to our growing portfolio of wholly owned, co-owned, and in-licensed intellectual property, now standing at over 115 granted or pending patent applications spread over 24 patent families.”

Bugworks Research Inc. to Present Eight Posters at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) 2023, in Copenhagen, Denmark

Retrieved on: 
Monday, April 17, 2023

and ADELAIDE, Australia, April 17, 2023 /PRNewswire/ -- Bugworks Research Inc., a clinical-stage biopharmaceutical company, is set to present its latest research findings on the novel bacterial topoisomerase inhibitor, BWC0977 at the upcoming 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Copenhagen, Denmark.

Key Points: 
  • and ADELAIDE, Australia, April 17, 2023 /PRNewswire/ -- Bugworks Research Inc., a clinical-stage biopharmaceutical company, is set to present its latest research findings on the novel bacterial topoisomerase inhibitor, BWC0977 at the upcoming 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Copenhagen, Denmark.
  • Bugworks Research is at the forefront of developing novel antibiotics to combat the growing threat of antimicrobial resistance.
  • The ECCMID conference is a leading global forum for infectious diseases and clinical microbiology.
  • Attendees are invited to visit the Bugworks Research booth to learn more about the company's innovative approach to fighting antibiotic resistance.

Bugworks Research Inc. to Present Eight Posters at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) 2023, in Copenhagen, Denmark

Retrieved on: 
Monday, April 17, 2023

and ADELAIDE, Australia, April 17, 2023 /PRNewswire/ -- Bugworks Research Inc., a clinical-stage biopharmaceutical company, is set to present its latest research findings on the novel bacterial topoisomerase inhibitor, BWC0977 at the upcoming 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Copenhagen, Denmark.

Key Points: 
  • and ADELAIDE, Australia, April 17, 2023 /PRNewswire/ -- Bugworks Research Inc., a clinical-stage biopharmaceutical company, is set to present its latest research findings on the novel bacterial topoisomerase inhibitor, BWC0977 at the upcoming 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Copenhagen, Denmark.
  • Bugworks Research is at the forefront of developing novel antibiotics to combat the growing threat of antimicrobial resistance.
  • The ECCMID conference is a leading global forum for infectious diseases and clinical microbiology.
  • Attendees are invited to visit the Bugworks Research booth to learn more about the company's innovative approach to fighting antibiotic resistance.

GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress

Retrieved on: 
Wednesday, April 5, 2023

Atlanta, GA, April 05, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the presentation of encouraging data from recent nonhuman primate studies of GeoVax’s vaccine candidate (GEO-MM01) against Marburg virus, during the 23rd Annual World Vaccine Congress taking place in Washington, DC.

Key Points: 
  • Atlanta, GA, April 05, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the presentation of encouraging data from recent nonhuman primate studies of GeoVax’s vaccine candidate (GEO-MM01) against Marburg virus, during the 23rd Annual World Vaccine Congress taking place in Washington, DC.
  • Dr. Comer’s presentation focused on UTMB’s services for regulated, nonclinical studies, and included data from recent studies conducted on behalf of GeoVax.
  • Of particular interest, immunization with GeoVax’s vaccine candidate (GEO-MM01) conferred 80% survival in cynomolgus macaques following a lethal dose of Marburg virus.
  • The vaccine induced immune responses were characterized by Marburg virus-specific binding and neutralizing antibodies as well as other effector functions like antibody-dependent phagocytosis.

GeoVax to Participate at the World Vaccine Congress with Multiple Presentations

Retrieved on: 
Thursday, March 30, 2023

Atlanta, GA, March 30, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it will be represented in two presentations during the upcoming 23rd Annual World Vaccine Congress taking place in Washington, DC on April 3-6, 2023.

Key Points: 
  • His presentation will focus on UTMB’s services for regulated, nonclinical studies, particularly surrounding therapies and prophylactics for Filoviruses.
  • The CM04S1 vaccine is an experimental COVID-19 vaccine based on the use of the MVA viral vector platform, which presents multiple antigens to the immune system to induce both antibody and T cell responses.
  • GeoVax is focusing on the clinical development of this vaccine for use in patients with special medical limitations or needs, specifically the partially immunocompromised population.
  • These individuals may not be able to raise or maintain protective antibody responses following receipt of first-generation mRNA vaccines, contributing to reduced vaccine efficacy.

29 Organizations Achieve Excellence in Respiratory Care

Retrieved on: 
Thursday, February 16, 2023

Irving, Feb. 16, 2023 (GLOBE NEWSWIRE) -- The American Association for Respiratory Care (AARC) has named 29 organizations from across the U.S. as recipients of the 2023-2024 Apex Recognition Award.

Key Points: 
  • Irving, Feb. 16, 2023 (GLOBE NEWSWIRE) -- The American Association for Respiratory Care (AARC) has named 29 organizations from across the U.S. as recipients of the 2023-2024 Apex Recognition Award.
  • The designation exemplifies best practices in the profession and promotes patient safety and outcomes by providing access to respiratory therapists who deliver high-quality respiratory care.
  • Congratulations to our 2023-2024 Apex Recognition Award recipients.”
    The AARC is dedicated to supporting the respiratory care profession.
  • The Apex award program distinguishes facilities for their commitment to excellence in professional development, evidence-based care, patient safety, patient satisfaction and quality improvement.

Clinical data presented at ASCO GU demonstrates reduced risk of recurrence in non-muscle invasive bladder cancer with the use of BLC

Retrieved on: 
Monday, February 20, 2023

The clinical data demonstrated a significant decrease in the risk of recurrence & longer time to recurrence following Blue Light cystoscopy (BLC®) with Cysview® compared to White Light cystoscopy (WLC) alone.

Key Points: 
  • The clinical data demonstrated a significant decrease in the risk of recurrence & longer time to recurrence following Blue Light cystoscopy (BLC®) with Cysview® compared to White Light cystoscopy (WLC) alone.
  • A significant decrease in risk of recurrence following BLC utilization compared to WLC alone was also determined (HR, 0.70, p=0.005).
  • "Our findings demonstrate increased support for blue light cystoscopy's clinical role in reducing bladder cancer recurrence, and that equal access to health care can achieve equitable outcomes.
  • These data support current AUA/SUO guidelines recommending BLC usage in patients with NMIBC to increase detection and decrease recurrence."